Treatment of refractory pemphigus erythematosus with rituximab

International Journal of Dermatology

Volumn 47, Issue 12, 2008, Pages 1317-1318

  Diab, Mohammad ^a   Bechtel, Mark ^a   Coloe, Jacquelyn ^b   Kurtz, Eleanor ^b   Ranalli, Mark ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DAPSONE; DESMOGLEIN 1 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ACANTHOLYSIS; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TREATMENT FAILURE; ERYTHEMATOUS PEMPHIGUS; FEMALE; HUMAN; HUMAN TISSUE; PAPULE; PLAQUE FORMING CELL; SKIN BIOPSY;

ADOLESCENT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; PEMPHIGUS;

EID: 57049172575     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2008.03682.x     Document Type: Article

References (13)

1. Senear FE, Usher B. An unusual type of pemphigus: Coming features of lupus erythematosus. Arch Dermatol Syphilol 1926; 13: 761.
2. Chorzelski J, Jacblonska S, Blaszczyk M. Immunopathological investigations in the Senear-Usher syndrome (coexistence of pemphigus and lupus erythematosus). Br J Dermatol 1968; 80: 211.
3. Diab M, Gallina K, Kurtz E, et al. Treatment of refractory pemphigus erythematosus with rituximab [Poster]. JAAD 2007; 56 (2 Suppl. 2): AB118.
4. Gupta MT, Jerajani HR. Control of childhood pemphigus erythematosus with steroids and azathioprine. Br J Dermatol 2004; 150: 163-164.
5. Rituximab Package Insert (Biogen Idec Inc, & Genentech, Inc 2005). Available at .
6. Goebeler M, Herzog S, Brocker EB, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol 2003; 149: 899-901.
7. Esposito M, Capriotti E, Giunta A, et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venerol 2006; 86: 87-89.
8. Barnadas M, Roe E, Brunet S, et al. Therapy of paraneoplastic pemphigus with Rituximab: A case report and review of literature. J Eur Acad Dermatol Venerol 2006; 20: 69-74.
9. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47: 785-788.
10. Espana A, Fernandez-Galar M, Lloret P, et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol 2004; 50: 974-976.
11. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol 2003; 2: 564-567.
12. Rossum MM, Verhaegen NT, Jonkman MF, et al. Follicular non-Hodgkin's lymphoma with refractory paraneoplastic pemphigus: Case report with review of novel treatment modalities. Leuk Lymphoma 2004; 45: 2327-2332.
13. Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: Case report. Pediatr Nephrol 2005; 20: 811-813.